NASDAQ:DYN • US26818M1080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DYNE THERAPEUTICS INC (DYN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-15 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-12-10 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-12-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-14 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-12 | Oppenheimer | Maintains | Perform -> Perform |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-10 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2025-08-25 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2025-08-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-31 | Stifel | Maintains | Buy -> Buy |
| 2025-07-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-29 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-07-15 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-06-26 | Jones Trading | Initiate | Buy |
| 2025-06-18 | Guggenheim | Reiterate | Buy -> Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 210.98% | N/A 202.34% | N/A 78.48% | N/A 26.23% | N/A 21.89% | N/A 12.78% | |||||||||
| EBITDA YoY % growth | -4.78M | -13.56M -183.68% | -57.95M -327.36% | -148.94M -157.01% | -169.28M -13.66% | -240.489M -42.07% | -342.213M -42.30% | -466.135M -36.21% | N/A -16.16% | N/A -8.22% | N/A 20.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.8M | -13.83M -188.13% | -58.65M -324.08% | -150.03M -155.81% | -170.96M -13.95% | -242.162M -41.65% | -343.886M -42.01% | -468.184M -36.15% | N/A -11.15% | N/A 1.05% | N/A 14.25% | N/A 113.41% | N/A 964.66% | N/A 34.34% | N/A 32.21% | N/A 15.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.91 -15.59% | -3.24 -11.34% | -3.94 -21.60% | -3.35 14.97% | -3.54 -5.67% | N/A 6.88% | N/A 7.71% | N/A 34.00% | N/A 126.16% | N/A 459.62% | N/A 63.00% | N/A 33.94% | N/A 14.90% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.79 24.36% | -0.84 13.32% | -0.86 -12.79% | -0.86 -13.29% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -128.27M -5.25% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -125.334M -2.42% | -127.85M -10.41% | -133.078M -16.85% | -135.54M -16.72% |
All data in USD
20 analysts have analysed DYN and the average price target is 41.48 USD. This implies a price increase of 142.01% is expected in the next year compared to the current price of 17.14.
DYNE THERAPEUTICS INC (DYN) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of DYNE THERAPEUTICS INC (DYN) is -0.79 USD and the consensus revenue estimate is 0 USD.